Bal Pharma Ltd
Bal Pharma Ltd (BALPHARMA) last traded at ₹85.6, a market capitalisation of ₹136 crore, on a P/E of 18.9. Over the past 52 weeks the stock has ranged between ₹59.7 and ₹99. Bal Pharma Ltd last reported results for the quarter ended Jun 2026, with sales of ₹88.62 crore and net profit of ₹1.13 crore. The next scheduled event is a record date on 30 Oct 2026. Figures are as of 25 Aug 2026 and are not real time.
Bal Pharma Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Bal Pharma Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹88.62 cr, up 34.5% from ₹65.87 cr a year earlier. Net profit was ₹1.13 cr, up 438.1% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 73.69 | 73.15 | 81.88 | 65.87 | 74.02 | 87.69 | 84.08 | 88.62 |
| Expenses | 66 | 65.4 | 74.24 | 59.81 | 68.29 | 78.15 | 73.5 | 80.67 |
| Operating profit | 7.69 | 7.75 | 7.64 | 6.06 | 5.73 | 9.54 | 10.58 | 7.95 |
| OPM % | 10.44% | 10.59% | 9.33% | 9.20% | 7.74% | 10.88% | 12.58% | 8.97% |
| Other income | -0.2 | 0.51 | 1.08 | 0.72 | 1.12 | 0.33 | -0.24 | 0.44 |
| Interest | 3.65 | 5.01 | 3.95 | 4.05 | 3.86 | 4.85 | 4.06 | 4.47 |
| Depreciation | 2.48 | 2.69 | 2.18 | 2.52 | 2.27 | 3.23 | 3.06 | 2.78 |
| Profit before tax | 1.36 | 0.56 | 2.59 | 0.21 | 0.72 | 1.79 | 3.22 | 1.14 |
| Tax % | 23.53% | 7.14% | -108.88% | 0.00% | 0.00% | 0.00% | -12.11% | 0.00% |
| Net profit | 1.04 | 0.52 | 5.41 | 0.21 | 0.72 | 1.79 | 3.6 | 1.13 |
| EPS (₹) | 0.65 | 0.30 | 3.41 | 0.13 | 0.45 | 1.12 | 2.25 | 0.70 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Bal Pharma Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 251 | 281 | 304 | 339 | 303 | 312 | 334 |
| Operating profit | 25 | 24 | 25 | 31 | 30 | 32 | 34 |
| OPM % | 10% | 9% | 8% | 9% | 10% | 10% | 10% |
| Net profit | 5 | 6 | 3 | 7 | 7 | 6 | 7 |
| EPS (₹) | 3.20 | 3.78 | 1.64 | 4.68 | 4.53 | 3.94 | 4.52 |
TTM is the trailing twelve months to the most recent quarter.
Bal Pharma Ltd growth and returns
- 10 Years
- 5%
- 5 Years
- 4%
- 3 Years
- 1%
- TTM
- 14%
- 10 Years
- 16%
- 5 Years
- 6%
- 3 Years
- 35%
- TTM
- 1%
- 10 Years
- -1%
- 5 Years
- -2%
- 3 Years
- -3%
- 1 Year
- -2%
- 10 Years
- 5%
- 5 Years
- 8%
- 3 Years
- 9%
- Last Year
- 8%
Bal Pharma Ltd shareholding pattern
Promoters held 50.87% at Jun 2026, broadly unchanged since Jun 2025. FIIs 0.15%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 50.87% | 50.87% | 50.87% | 50.87% | 50.87% | 50.87% | 50.87% | 50.87% |
| FIIs | 0.13% | 0.14% | 0.14% | 0.15% | 0.23% | 0.14% | 0.14% | 0.15% |
| Public | 49.01% | 49.00% | 49.01% | 48.99% | 48.91% | 49.01% | 49.01% | 48.99% |
| No. of shareholders | 16,007 | 15,667 | 15,723 | 15,826 | 15,774 | 15,520 | 15,214 | 14,974 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming Bal Pharma Ltd events
The next scheduled event is a record date on 30 Oct 2026.
- Record dateClaim unclaimed dividends and shares before transfer to IEPF
See the full results calendar for every Indian company reporting in the next 30 days.
Bal Pharma Ltd corporate filings
- This is in Continuation of Company earlier intimation made in connection with allotment of warrants , hereby clarify that utilization of net proceeds or tenure of warrants is 18 month from ....Company Updatelow impact
Cruxal's analysis: Bal Pharma Limited has issued a clarification regarding its preferential issue of…
Read the full analysis - In Continuation of Outcome of Board meeting dated August 12 2026 , Published Unaudited Financial result for the quarter ended 30th June 2026 and IEPF Notice in Financial express and Sanjevani ....Company Updatelow impact
Cruxal's analysis: Bal Pharma Limited has released its unaudited standalone and consolidated financial…
Read the full analysis - Enclosed Financial Result for the First quarter ended 30th June 2026 together with Limited Review Report as submitted by Statutory auditorResulthigh impact
Cruxal's analysis: Bal Pharma Limited reported standalone revenue from operations of 88.43 crore for the…
Read the full analysis - Board of directors of the Company met on Wednesday, August 12 2026 inter alia transacted the following business. 1. Considered and approved the unaudited Financial Results (Standalone ....Board Meetinghigh impact
Cruxal's analysis: Bal Pharma Limited reported Q1 FY27 standalone revenue of 88.43 crore and a net profit of…
Read the full analysis - Scrutinizers Report Pertaining to Postal Ballot Notice dated July 09 2026 read with its Corrigendum dated July 23rd 2026.AGM/EGMmedium impact
Cruxal's analysis: Bal Pharma Limited has received shareholder approval via postal ballot for the issuance…
Read the full analysis - Outcome : Result of Postal Ballot Notice dated July 09 2026 read with its Corrigendum dated July 23 , 2026AGM/EGMmedium impact
Cruxal's analysis: Bal Pharma Limited has received shareholder approval via postal ballot for the…
Read the full analysis - Bal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 and other ....Board Meetinglow impact
Cruxal's analysis: Bal Pharma Limited has issued a formal intimation regarding a Board of Directors meeting…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Bal Pharma Ltd
Cruxal reads every Bal Pharma Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.